


Guidance for Presentation of Economic Studies to ACIP

Tracy Lieu, MD, MPH
Mark Messonnier, PhD
Martin Meltzer, PhD

ACIP's Charter

- **“Committee deliberations. . . should include consideration of population-based studies such as efficacy, cost-benefit, and risk-benefit analysis”**
- **ACIP focuses on health and economic value, rather than financing or cost constraints**

Cost of Vaccine Doses Needed to Fully Immunize a Child from Birth to Age 17 Years, at Federal Contract Prices



Economic Presentations at ACIP

| Year | Month | Vaccination Program |
|------|-------|---|
| 2004 | Oct | Meningococcal |
| 2005 | Feb | Pertussis – adolescents |
| | June | Varicella 2 nd dose, hepatitis A |
| | Oct | Pertussis – adults |
| 2006 | Feb | HPV, rotavirus, pertussis – health care workers |
| | June | HPV, varicella 2 nd dose, zoster |
| | Oct | Zoster, rabies post-exp prophylaxis |
| 2007 | June | Financing, meningococcal |
| | Oct | Intranasal influenza for 2-4 yr olds |
| 2008 | Feb | Meningococcal for 2-10 yr olds, HPV for 27-45 yr olds |

Notice to Readers: Guidance for Presentation of Economic Studies to the Advisory Committee on Immunization Practices

The charter of the Advisory Committee on Immunization Practices (ACIP) states that committee deliberations on the appropriate use of vaccines should include consideration of population-based studies such as efficacy, cost-benefit, and risk-benefit analyses (*1*). As the number and cost of vaccines have increased, economic analyses have become an essential aspect of the development of policy recommendations for their use. To ensure that economic data presented to the ACIP and its working groups are of the highest scientific quality, readily understandable, and uniform in presentation, CDC economists have developed Guidance for Health Economics Studies Presented to the ACIP. This guidance, approved by ACIP on June 27, 2007, mandates formal technical review of any economic study before its presentation to the ACIP, effective as of the ACIP meeting, June 25-26, 2008.

The Guidance requires that all economic data presented to the ACIP be reviewed by anonymous peer reviewers within CDC. When a reviewer with a particular area of economic expertise is not available within CDC, external reviewers may be used. Materials to be submitted for review must include a report that provides the methods and results of the study, slides, and other presentation materials as needed. The report and other materials must be sent to the appropriate ACIP working group no later than 8 weeks before the ACIP general meeting or working group meeting at which the analysis is scheduled to be presented. Reviewers will consult with relevant CDC subject-matter experts and return comments and questions in writing to the National Center for Immunization and Respiratory Diseases lead economist (or designee) at least 4 weeks in advance of the formal presentation. Additional details are included in the guidance document, which is available at <http://www.cdc.gov/vaccines/recs/acip/economic-studies.htm>.

Guidance

- **Submit a written report of methods and results; also, slides and other presentation materials**
- **8 weeks in advance of the meeting (of the ACIP working group or the ACIP)**
- **Reviewers will return comments**
- **Effective for June 2008 meeting and future**

**Special thanks to
Larry Pickering
and Jean Smith**

<http://www.cdc.gov/vaccines/recs/acip/economic-studies.htm>